| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00787644 Details | 2015-02-26 Interventional | 2 | 28 | Pioglitazone Asthma Obesity | new safety concerns which emerged about pioglitazone during the trial Early termination leading to small numbers of subjects analyzed | |||
| NCT02113891 Details | 2015-02-25 Interventional | 1/2 | 0 | Eculizumab Subclinical Acu… | disengagement of the sponsor Alexion Pharmaceuticals - | |||
| NCT00934739 Details | 2015-02-25 Interventional | 2/3 | 150 | Celecoxib Cyclophosphamid… Dexamethasone Thalidomide Mouth Neoplasms Oral Cavity Can… | - - | |||
| NCT00529503 Details | 2015-02-25 Interventional | 2 | [1 Refs] | 151 | Carboplatin Dacetuzumab Etoposide Ifosfamide Rituximab Lymphoma Lymphoma, Large… Lymphoma, Non-H… | - - | ||
| NCT00376428 Details | 2015-02-25 Interventional | 2 | - | Gentamicins Cystic Fibrosis Fibrosis | - - | |||
| NCT01995058 Details | 2015-02-20 Interventional | 2 | 54 | Abiraterone Ace… Prednisone Prostatic Neopl… Castration Resi… Prostate Cancer | Study stopped after results of cabozantinib Phase 3 CRPC study XL184-307. - | |||
| NCT00816166 Details | 2015-02-20 Interventional | 2/3 | 125 | Aspirin Clopidogrel Ischemia Ischemic Attack… Ischemic Stroke Transient Ische… | - Early termination of enrollment led to small numbers of subjects analyzed (less than 50% of the prospectively planned sample size). Various endpoints, subgroup and sensitivity analyses were not conducted because the study was not fully enrolled. | |||
| NCT00375596 Details | 2015-02-20 Interventional | 2 | 0 | Ketotifen Vasoconstrictor… Conjunctivitis Conjunctivitis,… Allergic Conjun… | Study withdrawn without starting or enrolling subjects due to a business decision to not
proceed with the project. - | |||
| NCT00767000 Details | 2015-02-19 Interventional | 2 | [1 Refs] | 813 | Insulin Glargin… Metformin Diabetes Mellit… Diabetes Mellit… | - - | ||
| NCT02246816 Details | 2015-02-18 Interventional | 3 | 0 | Opium Short Bowel Syn… Syndrome SBS Short Gut Short Gut Syndr… | Transfer of IND to different marketing authorization representative. - | |||
| NCT02242656 Details | 2015-02-18 Interventional | 3 | 0 | Opium Short Bowel Syn… Syndrome SBS Short Bowel Short Gut Short Gut Syndr… | Transfer of IND to new marketing authorization holder - | |||
| NCT01013831 Details | 2015-02-18 Interventional | 1 | 60 | Erlotinib Hydro… Metaplasia Precancerous Co… Dysplasia Pulmonary Preca… | - - | |||
| NCT00960934 2009-012926-35 Details | 2015-02-18 Interventional | 2 | [1 Refs] | 383 | Calcium Calcium Carbona… Cholecalciferol Vitamin D Osteoporosis | - - | ||
| NCT01592773 Details | 2015-02-16 Interventional | 2 | 747 | Memantine Asperger Syndro… Autism Spectrum… Autistic Disord… Child Developme… Developmental D… Asperger's Asperger's Diso… Autism Autism Spectrum… Pediatric Autis… Pervasive Devel… | Terminated because primary efficacy parameter failed to demonstrate statistically significant
difference between memantine and placebo in controlled trials - | |||
| NCT00513253 Details | 2015-02-16 Interventional | 1 | 0 | Lapatinib Healthy Subject… | It was determined not to be needed based on the clinical development plan of Tykerb. - | |||
| NCT01111448 Details | 2015-02-13 Interventional | 2 | 20 | MTOR Inhibitors Sirolimus Temsirolimus Myelodysplastic… Preleukemia Syndrome Myelodysplastic… | Unfavourable Risk-Benefit-Ratio - | |||
| NCT00430742 Details | 2015-02-13 Interventional | 3 | [1 Refs] | 600 | N-(3-(4-chlorop… Diabetes Mellit… Diabetes Mellit… Obesity Type 2 … Type 2 Diabetes… | The overall profile does not support development for obesity - | ||
| NCT00363883 Details | 2015-02-13 Interventional | 2 | 14 | Vorinostat Carcinoma Carcinoma, Tran… Kidney Neoplasm… Recurrence Ureteral Neopla… Urinary Bladder… Localized Trans… Metastatic Tran… Recurrent Trans… Regional Transi… Transitional Ce… | Trial stopped early for futility Study was terminated early after the first stage of a two-stage design, allowing for early termination for discouraging results. | |||
| NCT00958776 Details | 2015-02-12 Interventional | 3 | 405 | Peramivir Headache Influenza, Huma… Pharyngitis Cough Fever Nasal Congestio… Seasonal Influe… Sore Throat | This study was terminated for futility Interim analysis of the primary efficacy endpoint (time to clinical resolution) performed after the end of the 2012 Southern Hemisphere influenza season lead to study termination for futility. Final enrollment was ~70% of the planned enrollment. | |||
| NCT02218762 Details | 2015-02-11 Interventional | 1 | 0 | Fluticasone Fluticasone-Sal… Salmeterol Xina… Xhance Asthma | It was decided that data from this study are no longer required and therefore it is not
necessary to expose patients to the study medication - |